LB Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-85.69	-25.21	-63.1	-6.28	-14.35
Depreciation & Amortization	0.18	0.32	0.09	0	0
Stock-Based Compensation	10.69	4.19	3.16	0.3	0.43
Other Adjustments	0.34	-0.86	3.49	-4.81	11.1
Changes in Accounts Payable	19.54	-0.91	5.02	1.1	0.13
Changes in Other Operating Activities	-27.63	-12.74	-1.7	-2.41	-0.05
Operating Cash Flow	-82.4	-35.21	-53.05	-12.09	-2.73
Operating Cash Flow Growth	-	-	-	-	-
Capital Expenditures	-0.44	-0.05	-0.77	-0.03	-
Purchases of Investments	-54.58	-44.84	-29.75	-33.99	-
Proceeds from Sale of Investments	10.2	5	53.75	6	0.12
Investing Cash Flow	-44.82	-39.89	23.23	-28.01	0.12
Long-Term Debt Issued	-	-	-	0.64	22.34
Net Long-Term Debt Issued (Repaid)	-	-	-	0.64	22.34
Issuance of Common Stock	100	302.56	0.02	0	-
Net Common Stock Issued (Repurchased)	100	302.56	0.02	0	-
Issuance of Preferred Stock	-	-	38.29	33.04	0.62
Net Preferred Stock Issued (Repurchased)	-	-	38.29	33.04	0.62
Other Financing Activities	-6.27	-	-	-	-
Financing Cash Flow	396.37	302.56	38.32	33.68	22.96
Net Cash Flow	269.16	227.47	8.5	-6.43	20.36
Free Cash Flow	-82.83	-35.26	-53.82	-12.12	-2.73
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Per Share	-3.70	-4.38	-150.24	-42.20	-11.81
Levered Free Cash Flow	-94.03	-38.59	-60.47	-6.97	8.08
Unlevered Free Cash Flow	-103.48	-43.79	-62.2	-12.71	-2.72

SEC Filings: 10-K · 10-Q